CD47-SIRPα Blockade Enhances Antibody Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic antibodies, such as rituximab, often exhibit limited efficacy in treating cancer due to cancer cells' resistance to immune-mediated killing mechanisms, with the CD47-SIRPα interaction being a key inhibitory signal that suppresses antibody-dependent cell-mediated cytotoxicity (ADCC).
Innovation Solution
Inhibiting the interaction between CD47 and SIRPα using antagonistic antibodies or agents that reduce or prevent inhibitory signal transduction, thereby enhancing the activity of immune effector cells against aberrant cells, such as cancer cells, by blocking the CD47-SIRPα complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibodies are used to treat cancer, then cancer cells are targeted for destruction, but cancer cells resist immune-mediated killing through CD47-SIRPα interaction
Solution Approach 1:
The patent introduces an intermediary substance (anti-CD47 antibody or small molecule inhibitor) that mediates between the therapeutic antibody and the cancer cell. This intermediary blocks the CD47-SIRPα interaction, removing the resistance mechanism and allowing the therapeutic antibody to effectively trigger immune effector cells against the cancer cell.
Solution Approach 2:
The patent extracts or removes the harmful inhibitory signal (CD47-SIRPα interaction) from the system. By using anti-CD47 antibodies or inhibitors, the patent separates and eliminates the resistance mechanism, allowing the therapeutic antibody to function effectively without being blocked by the CD47-SIRPα pathway.
2Productivity
If CD47-SIRPα interaction is present, then immune effector cell activity is suppressed, but blocking this interaction enhances ADCC
Solution Approach 1:
The patent converts the harmful inhibitory signal (CD47-SIRPα interaction that suppresses immune activity) into a beneficial target for therapy. By developing anti-CD47 antibodies or inhibitors, the patent transforms the resistance mechanism into a vulnerability, where blocking the interaction enhances ADCC and improves cancer cell destruction.
3Device complexity
If therapeutic antibody alone is used, then treatment is simple, but efficacy is limited due to cancer cell resistance
Solution Approach 1:
The patent merges the therapeutic antibody with a CD47-blocking agent (anti-CD47 antibody or small molecule inhibitor) to create a combination treatment. This combination overcomes the resistance mechanism while maintaining treatment feasibility, as the CD47 blocker can be administered concurrently or in sequence with the therapeutic antibody.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the in vivo efficacy of therapeutic antibodies by enhancing ADCC, potentially lowering treatment costs, improving cure and survival rates, and expanding the range of effective antibody therapeutics.
Implementation Method 1
the immune system's response to an antigen. Among the cells are macrophages, granulocytes, dendritic cells, natural killer cells and lymphocytes... Several different types of cells are involved in the immune system's response to an antigen... Among the lymphocytes cells are B cells (B lymphocytes), T cells (T lymphocytes), Killer T and Helper T cells
Implementation Method 2
the CD47-SIRPα interaction being a key inhibitory signal that suppresses antibody-dependent cell-mediated cytotoxicity (ADCC)
Data Source
AI summary
The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.